Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    Open Studies | "Haemophilus influenzae type b"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Haemophilus influenzae type b" (6 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine,Freeze-dried
Condition: Haemophilus Influenzae Type b Infections
Interventions: Biological: Minhai-HIB;   Biological: Act-HIB®
2 Recruiting A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix® -IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
Conditions: Haemophilus Influenzae Type B Vaccines;   Diphtheria;   Hepatitis B;   Tetanus;   Pertussis
Intervention: Biological: Infanrix® -IPV/Hib
3 Recruiting Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age
Conditions: Meningitis;   Meningococcal Meningitis;   Meningococcal Infections
Interventions: Biological: Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free);   Biological: Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant)
4 Recruiting Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
Conditions: Acellular Pertussis;   Tetanus;   Poliomyelitis;   Diphtheria
Interventions: Biological: Infanrix hexa;   Drug: Prevnar13
5 Recruiting Evaluate Safety of ComBe Five (Liquid) in Healthy Vietnamese Children Aged From 8 - 10 Weeks as a 3-dose Series, Interval for Each Dose is 4 Weeks
Condition: Safety, Pentavalent Vaccine
Intervention: Biological: ComBe Five (Liquid)
6 Not yet recruiting Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
Conditions: Diphtheria;   Hepatitis B;   Acellular Pertussis;   Haemophilus Influenzae Type b;   Tetanus;   Poliomyelitis
Intervention: Biological: Infanrix hexa

Study has passed its completion date and status has not been verified in more than two years.